Shahid Beheshti University Medical Sciences, Tehran, Iran.
Infection disease specialist, postdoc in diabetic foot, social security fund, Moayri Hospital, Tehran, Iran.
Can J Diabetes. 2014 Feb;38(1):5-8. doi: 10.1016/j.jcjd.2013.08.271.
Diabetic foot ulcers are one of the most important causes of lower limb amputations worldwide. The conventional treatments of diabetic foot ulcers are costly and often require patients to be hospitalized for long periods of time, thus representing a huge burden on any health care system. The use of autologous platelet-rich plasma (PRP), which is rich in multiple growth factors, may bear some similarities to the natural wound healing process. Nonetheless, few studies on human subjects have so far addressed the efficacy of PRP as a novel and minimally invasive treatment. Today, there is only 1 approved and available system to separate PRP from a patient's own blood in order to be used in diabetic ulcers. This system incorporates bovine thrombin for activation of PRP gel and may be applied by many healthcare providers without the need for extensive special training. In this report, a patient with extensive diabetic foot ulcers, non-responsive to other treatment modalities, was successfully treated by PRP.
糖尿病足溃疡是全球下肢截肢的最重要原因之一。糖尿病足溃疡的传统治疗方法费用高昂,往往需要患者住院很长时间,因此给任何医疗体系都带来了巨大的负担。使用富含多种生长因子的自体富血小板血浆(PRP)可能与自然伤口愈合过程有些相似。尽管如此,目前很少有针对人类受试者的研究探讨 PRP 作为一种新型微创治疗方法的疗效。目前,只有一种经过批准和可用于从患者自身血液中分离 PRP 以用于治疗糖尿病溃疡的系统。该系统采用牛凝血酶激活 PRP 凝胶,许多医疗服务提供者都可以使用,而无需进行广泛的特殊培训。在本报告中,一位对其他治疗方法反应不佳的广泛糖尿病足溃疡患者成功地接受了 PRP 治疗。